{"id":"apilimod-dimesylate-capsule","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by inhibiting the sphingosine 1-phosphate receptor 1 (S1P1), which plays a role in the immune system. This action can help reduce inflammation and modulate the immune response.","oneSentence":"Apilimod Dimesylate Capsule is a sphingosine 1-phosphate receptor modulator.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:57:00.719Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT05163886","phase":"PHASE2","title":"Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"OrphAI Therapeutics","startDate":"2021-12-23","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":14},{"nctId":"NCT02594384","phase":"PHASE1","title":"A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"OrphAI Therapeutics","startDate":"2015-10","conditions":"Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic","enrollment":62},{"nctId":"NCT04446377","phase":"PHASE2","title":"A Study of LAM-002A for the Prevention of Progression of COVID-19","status":"COMPLETED","sponsor":"OrphAI Therapeutics","startDate":"2020-07-15","conditions":"COVID-19 Disease","enrollment":142},{"nctId":"NCT05483322","phase":"","title":"An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)","status":"NO_LONGER_AVAILABLE","sponsor":"OrphAI Therapeutics","startDate":"","conditions":"Frontotemporal Dementia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Apilimod Dimesylate Capsule","genericName":"Apilimod Dimesylate Capsule","companyName":"OrphAI Therapeutics","companyId":"orphai-therapeutics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Apilimod Dimesylate Capsule is a sphingosine 1-phosphate receptor modulator. Used for Relapsing multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}